Supernus (SUPN) Q4 2025: Growth Portfolio Drives 76% of Revenue as Supply Constraints Ease
Supernus Pharmaceuticals’ fourth quarter marked a decisive shift toward its four-product growth engine, now contributing the majority of revenue and setting the stage for accelerated 2026 expansion. Supply constraints on Onapco have been largely resolved, and integration of Sage Therapeutics is delivering both pipeline optionality and commercial upside. Management’s guidance signals confidence in execution, but margin pressure and integration costs remain front of mind for investors.
Summary
- Growth Engine Dominance: Four key products now anchor revenue and future expansion, reducing legacy risk.
- Operational Resilience: Supply chain resolution for Onapco unlocks new patient initiations and backlog conversion.
- Strategic Flexibility: Cash-rich balance sheet supports late-stage pipeline and targeted M&A, despite margin headwinds.
Performance Analysis
Supernus delivered record fourth quarter revenue, with total sales up 21% year-over-year and growth products comprising 76% of the mix. Calvary, the ADHD therapy, exceeded $300 million in annual net sales, growing 26% and maintaining leadership in both adult and pediatric markets. GoCoveri, epilepsy treatment, posted double-digit growth, while Zerzuve, postpartum depression therapy, showed rapid adoption post-Sage acquisition, with collaboration revenue of $32.8 million and a 70% repeat prescriber rate. Onapco, launched into the Parkinson’s market, reached $8.9 million in quarterly sales despite prior supply constraints, and finished its first year at $17.3 million.
Legacy products Trochendi XR and Oxtelra XR have faded in importance, as the company’s growth portfolio now drives both volume and margin trajectory. Gross-to-net deductions, especially for Calvary, weighed on quarterly net sales due to a $4 million PBM clawback, resulting in a 49% gross-to-net ratio for the year. Operating expenses, elevated by Sage integration and intangible amortization, led to a GAAP loss, though non-GAAP operating earnings were stable year-over-year at $48.5 million. Cash reserves remain strong at $309 million, providing flexibility for future BD and pipeline investments.
- Growth Product Outperformance: Four-product portfolio now anchors 76% of revenue, insulating against legacy erosion.
- Margin Drag from PBM and Integration: Gross-to-net and Sage-related costs drove GAAP operating loss despite underlying growth.
- Cash Position Strength: $309 million in cash and no debt enables continued investment and M&A optionality.
Supernus’ transition to a diversified CNS-focused portfolio is now visible in the numbers, with operational and commercial momentum offsetting near-term margin dilution from integration and launch investments.
Executive Commentary
"With our four growth products, Calvary, GoCoveri, Zerzuve, and Onapco, we have built a solid foundation for a new phase of accelerated growth for Supernus. During the fourth quarter of 2025, revenues from these four growth products accounted for approximately 76% of total revenue."
Jack Attar, Chief Executive Officer
"The company's balance sheet remained strong with no debt and significant financial flexibility for potential M&A and other growth opportunities."
Tim Deck, Chief Financial Officer
Strategic Positioning
1. Growth Portfolio Supplants Legacy Revenue
Supernus’ business model is now centered on four CNS (central nervous system) growth assets—Calvary, GoCoveri, Zerzuve, and Onapco—which together comprise over three-quarters of total revenue. This shift reduces exposure to patent expirations and generic competition, while creating a more resilient revenue base with multiple growth vectors.
2. Supply Chain and Launch Execution for Onapco
Onapco, a novel Parkinson’s therapy, overcame supply constraints that limited new patient starts in 2025. Management confirmed that current suppliers can meet 2026 demand, and a second supplier (the company’s European partner) is expected to provide expanded capacity from 2027. This ensures continuity and supports backlog conversion, with more than 1,800 enrollment forms in process and a growing prescriber base.
3. Sage Acquisition: Integration and Pipeline Leverage
The Sage Therapeutics acquisition has added Zerzuve to the commercial portfolio and expanded the early-stage pipeline. Supernus is prioritizing late-stage, revenue-generating assets for business development, but will retain select early-stage programs for internal development. The integration brings both commercial upside and near-term cost pressure from higher SG&A and amortization.
4. Commercial Execution and Market Development
Calvary and GoCoveri continue to deliver double-digit prescription growth, while Zerzuve’s launch is being supported by direct-to-consumer (DTC) campaigns and physician education to expand market penetration. Management sees significant headroom in postpartum depression, with only a fraction of the addressable population treated to date. Repeat prescriber rates and script growth trends indicate positive product-market fit.
5. Financial Flexibility and Capital Deployment
With $309 million in cash and no debt, Supernus is positioned to pursue additional M&A or late-stage pipeline deals. Management is focused on opportunities that can deliver new launches in the 2027-2031 window, balancing organic pipeline advancement with external growth levers.
Key Considerations
Supernus enters 2026 with a transformed revenue base, operational tailwinds from supply normalization, and a clear focus on CNS-driven growth. However, investors must weigh ongoing integration costs, margin volatility, and the execution risk tied to pipeline and commercial launches.
Key Considerations:
- Growth Product Reliance: Four key brands now drive the business, but concentrated risk remains if any underperform.
- Supply Chain Continuity: Onapco’s supply constraints have been resolved for 2026, but execution on second supplier onboarding is a watchpoint for 2027 and beyond.
- Integration Drag: Sage acquisition delivers commercial and pipeline upside, but integration costs and amortization weigh on GAAP profitability.
- Pipeline Visibility: Late-stage pipeline readouts for SPN817 and SPN820 are not expected before 2027, limiting near-term clinical catalysts.
- Capital Allocation: Strong cash position supports strategic flexibility, but management signaled a bias toward late-stage or commercial-ready assets.
Risks
Margin compression from gross-to-net deductions and integration costs could persist, especially if PBM clawbacks remain elevated or launch investments escalate. Supply chain risks have abated for 2026, but onboarding a new Onapco supplier in 2027 introduces regulatory and operational uncertainty. Pipeline delays or commercial underperformance of the four key growth brands would materially impact the business, given their outsized contribution to revenue and growth.
Forward Outlook
For Q1 2026, Supernus expects:
- Continued prescription and sales growth across Calvary, GoCoveri, and Zerzuve, with Onapco ramping as supply normalizes.
- Gross-to-net ratios to remain elevated in Q1, then normalize as the year progresses.
For full-year 2026, management guided to:
- Total revenue of $840 million to $870 million, with $45 million to $70 million from Onapco.
- Combined R&D and SG&A expenses of $620 million to $650 million.
- Non-GAAP operating earnings of $140 million to $170 million.
Management highlighted:
- Supply chain stability for Onapco through 2026, with second supplier onboarding in 2027.
- Ongoing investment in commercial execution and market education for Zerzuve and Calvary.
Takeaways
Supernus’ transition to a multi-product CNS growth platform is now visible in both financials and execution, but investors should monitor margin pressures and the pace of pipeline advancement.
- Growth Portfolio Execution: Four key products have replaced legacy revenue, but the business remains exposed to concentrated product risk and launch execution challenges.
- Integration and Margin Watch: Sage acquisition delivers commercial leverage, but integration and amortization costs are a near-term drag on GAAP profitability.
- 2026 Focus: Investors should watch for sustained script growth, successful Onapco backlog conversion, and updates on late-stage pipeline progress or BD activity.
Conclusion
Supernus enters 2026 with a diversified, growth-driven CNS portfolio and strong cash reserves, but integration costs and supply chain execution will remain key areas of investor focus. The company’s ability to translate commercial momentum into sustained margin expansion and pipeline progress will determine long-term value creation.
Industry Read-Through
Supernus’ results highlight the increasing importance of diversified product portfolios in specialty pharma, as legacy exclusivity fades and payor dynamics drive margin volatility. The rapid adoption of Zerzuve in postpartum depression suggests significant untapped demand in underdiagnosed CNS and women’s health categories. Supply chain resilience and commercial agility will remain critical differentiators for companies launching new CNS therapies, especially those reliant on specialty distribution and complex patient onboarding. Investors should monitor how other CNS and specialty pharma players manage gross-to-net pressures and balance late-stage pipeline investment with near-term commercial execution.